Clinical trials: Asthma Patients
Asthma
Observational Study on the Clinical Profile of Patients With Uncontrolled Severe Asthma Treated With Tezepelumab in Italy
This observational study aims to collect data in clinical practice on the clinical profile of patients treated with Tezepelumab from Q1 2024 to Q1 2025 according to the approved and reimbursed indication in Italy
- Trial name
- FRONTEDGE (NCT06948396)
- Testing
- Tezepelumab
- Where
- 28 sites in Italy
- Volunteers
- 315 people
- Sponsor
- AstraZeneca
Asthma
Specific Use-Result of Spiriva Respimat® in Asthmatics
The study objective is to investigate the safety and effectiveness of Spiriva Respimat in patients with mild to moderate persistent asthma under real-world use
- Trial name
- NCT03188120
- Testing
- Spiriva Respimat
- Where
- Japan
- Volunteers
- 193 people
- Sponsor
- Boehringer Ingelheim
Asthma
Study in Patients With Asthma
The purpose of this study is to determine which dose of the investigational drug is the most safe and effective in the treatment of asthma compared to the control drug.
- Trial name
- NCT00215397
- Testing
- Formoterol Fumarate
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Dey
Asthma
A Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for Four Weeks in Patients With Moderate Persistent Asthma
Rationale for the current trial is to demonstrate 24 hour bronchodilator efficacy and safety of tiotropium 5 µg administered once daily (in the evening) which is regarded beneficial for the compliance and convenience of the…
- Trial name
- NCT01152450
- Testing
- Tiotropium 2.5 µg b.i.d, Tiotropium 5 µg q.d.
- Where
- 15 sites in Austria, Czechia and 3 more
- Volunteers
- 94 people
- Sponsor
- Boehringer Ingelheim
Asthma
Flutiform in Treatment of Patients With Asthma in Daily Clinical Practice.
The objective of the study is to evaluate the effect of frequency of use with a spacer on asthma control in Dutch patients with asthma during their daily clinical practice over 12 weeks treatment.
- Trial name
- NCT02811315
- Testing
- Observational. Non interventional study
- Sponsor
- Mundipharma Pharmaceuticals B.V.
Asthma
Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients
Primary objective To show the superiority of CHF 1535 (BDP/FF) pMDI (800/24 μg per day) over BDP HFA pMDI (800 μg per day) in terms of change from baseline to the entire treatment period in average pre-dose morning peak…
- Trial name
- FORCE (NCT01577082)
- Testing
- CHF1535 200/6 µg pMDI, BDP HFA 100 µg pMDI
- Where
- 66 sites in Bulgaria, Czechia and 7 more
- Volunteers
- 542 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Allergic Rhinoconjunctivitis
Subcutaneous Immunotherapy in Patients Sensitized to Dermatophagoides Pteronyssinus (DPT)
Based on EMA (European Medicines Agency) new guidelines on the clinical development of products for immunotherapy for the treatment of allergic diseases the aim of this study was to assess safety and tolerability of 3 different…
- Trial name
- NCT01489020
- Testing
- subcutaneous immunotherapy with DPT extract
- Where
- 2 sites in Spain
- Volunteers
- 48 people
- Sponsor
- Roxall Medicina España S.A
Asthma
A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication
This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of lebrikizumab in participants with asthma whose disease remains uncontrolled despite daily treatment…
- Trial name
- NCT01867125
- Testing
- Lebrikizumab
- Where
- 181 sites in United States, Argentina and 24 more
- Volunteers
- 1,081 people
- Sponsor
- Hoffmann-La Roche
Asthma
Study in Patients With Asthma
The purpose of this study is to determine which dose of the investigational drug is safest and most effective compared to the control drug.
- Trial name
- NCT00215358
- Testing
- Formoterol Fumarate
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Dey
Asthma, Airway Obstruction
Single-dose Crossover Study to Investigate Pharmacodynamics of AZD3199
The purpose of this study is to investigate the pharmacodynamics of single doses of AZD3199 in asthmatic patients.
- Trial name
- NCT00736489
- Testing
- AZD3199, Formoterol
- Where
- 4 sites in Denmark, Sweden
- Volunteers
- 37 people
- Sponsor
- AstraZeneca
Asthmatic Patients
FACTO Study (Foster® As Complete Treatment Option)
Double blind, multinational, multicentre, randomised, 2 arm parallel group study
- Trial name
- FACTO (NCT00901368)
- Testing
- FOSTER, Seretide
- Where
- 4 sites in France, Germany and 2 more
- Volunteers
- 431 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Study in Patients With Asthma
The purpose of this study is to determine the most safe and effective dose of the investigational drug in comparison with a control drug and placebo.
- Trial name
- NCT00215410
- Testing
- Formoterol Fumarate
- Where
- 12 sites in United States
- Volunteers
- 36 people
- Sponsor
- Dey
Asthma
Safety and Efficacy of Two Dosages of Inhaled TPI ASM8 Compared to Placebo in Mild to Moderate Asthmatic Patients
This study will evaluate the efficacy, safety and tolerability of two dosages of a new drug TPI ASM8 administered by inhalation for 14 days to mild to moderate asthmatic patients, aged between 18-65, non-smokers .
- Trial name
- NCT00402948
- Testing
- TPI ASM8, ASM8
- Where
- 10 sites in Canada
- Volunteers
- 10 people
- Sponsor
- Syntara
Asthma
Change in Patient-Reported Outcomes in Severe Eosinophilic Asthma Patients Treated With Benralizumab Under Real-life Conditions
The main aim of this study is to investigate the change in asthma control after 6 months of therapy in patients treated with benralizumab biologic therapy for severe eosinophilic asthma under real-life conditions in a pulmonary…
- Trial name
- imPROve (NCT04184284)
- Where
- 50 sites in Germany
- Volunteers
- 246 people
- Sponsor
- AstraZeneca
Asthma
Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Participants With Asthma
This study is conducted to assess whether training participants on proper use of BF SPIROMAX and Symbicort TURBOHALER will improve their device-handling technique and potentially improve their treatment outcome, that is, better…
- Trial name
- ELIOT (NCT02062463)
- Testing
- Budesonide and formoterol fumarate dehydrate (BF) SPIROMAX, SYMBICORT TURBOHALER budesonide and formoterol fumarate
- Where
- 74 sites in United Kingdom
- Volunteers
- 485 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
Safety Study of Nebulized RNS60 to Treat Asthma.
The purpose of this study is two-fold. First, to determine whether nebulized RNS60 is safe in healthy human subjects and in subjects with mild asthma, in a single-dose administration.
- Trial name
- NCT01057498
- Testing
- RNS60, RNS60 - single dose
- Where
- 2 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Revalesio Corporation
Bronchial Asthma
Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®)
The aim of this study was to compare the efficacy and tolerability of the fixed combination beclomethasone/formoterol pMDI with that of budesonide/formoterol dry powder via Turbuhaler.
- Trial name
- NCT00413387
- Testing
- beclomethasone dipropionate plus formoterol fumarate combination, budesonide plus formoterol combination
- Where
- 13 sites in Austria, Poland and 1 more
- Volunteers
- 219 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
CYT003 in Patients With Mild to Moderate Allergic Asthma Not Sufficiently Controlled on Inhaled Glucocorticosteroids
A phase IIb study in patients to evaluate CYT003- QbG10 versus placebo, in patients with mild to moderate allergic asthma not sufficiently controlled on inhaled steroid.
- Trial name
- NCT02087644
- Testing
- CYT003
- Where
- United States
- Sponsor
- Cytos Biotechnology AG
Asthma
Effect of Inhaled TD-8236 on Allergen-induced Asthmatic Response
This will be a randomized, double-blind, placebo-controlled study. The study will use a three-period, six-sequence, complete-block, cross-over study design to characterize two doses of inhaled TD-8236 compared to placebo in…
- Trial name
- NCT04150341
- Testing
- TD-8236
- Where
- 2 sites in United Kingdom
- Volunteers
- 24 people
- Sponsor
- Theravance Biopharma
Asthma
To Evaluate the Inflammatory Markers in Adult Patients With Asthma Associated With Allergic Rhinitis Receiving Montelukast Therapy (0476-366)
To evaluate the changes in proinflammatory markers (ltd4 in urine) and eosinophil from peripheral blood after newly initiated montelukast therapy.
- Trial name
- NCT00398151
- Testing
- MK0476, montelukast sodium / Duration of Treatment: 12 Weeks
- Volunteers
- 58 people
- Sponsor
- Organon and Co